Comment
doi: 10.1016/j.cmet.2007.12.006.
Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies?
Affiliations
- PMID: 18177717
- DOI: 10.1016/j.cmet.2007.12.006
Item in Clipboard
Comment
Taranabant cuts the fat: new hope for cannabinoid-based obesity therapies?
Cell Metab.
2008 Jan.
Free article
Abstract
Endocannabinoid/cannabinoid receptor signaling acts centrally and peripherally to govern appetite and energy balance. While system stimulation promotes eating and energy storage, receptor blockade can reduce food intake and facilitate weight loss. In this issue of Cell Metabolism, Addy et al. (2008) test the therapeutic antiobesity potential of taranabant, a cannabinoid 1 receptor inverse agonist.
Comment on
-
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.Cell Metab. 2008 Jan;7(1):68-78. doi: 10.1016/j.cmet.2007.11.012. Cell Metab. 2008. PMID: 18177726 Clinical Trial.
Similar articles
-
The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.Arch Pharm (Weinheim). 2008 Jul;341(7):405-11. doi: 10.1002/ardp.200700255. Arch Pharm (Weinheim). 2008. PMID: 18574849 Review.
-
Cannabinoid-1 receptor inverse agonists: current understanding of mechanism of action and unanswered questions.Int J Obes (Lond). 2009 Sep;33(9):947-55. doi: 10.1038/ijo.2009.132. Epub 2009 Jul 14. Int J Obes (Lond). 2009. PMID: 19597516 Review.
-
Taranabant, a novel cannabinoid type 1 receptor inverse agonist.Curr Opin Investig Drugs. 2008 Oct;9(10):1116-29. Curr Opin Investig Drugs. 2008. PMID: 18821475 Review.
-
A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet.Obesity (Silver Spring). 2010 Dec;18(12):2301-10. doi: 10.1038/oby.2010.67. Epub 2010 Apr 8. Obesity (Silver Spring). 2010. PMID: 20379151 Free PMC article. Clinical Trial.
-
The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake.Cell Metab. 2008 Jan;7(1):68-78. doi: 10.1016/j.cmet.2007.11.012. Cell Metab. 2008. PMID: 18177726 Clinical Trial.
Cited by
-
Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats.Diabetes. 2008 Nov;57(11):2977-91. doi: 10.2337/db08-0161. Epub 2008 Aug 20. Diabetes. 2008. PMID: 18716045 Free PMC article.
-
Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development.Curr Top Med Chem. 2019;19(16):1418-1435. doi: 10.2174/1568026619666190708164841. Curr Top Med Chem. 2019. PMID: 31284863 Free PMC article. Review.
-
Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.Addict Biol. 2008 Jun;13(2):239-52. doi: 10.1111/j.1369-1600.2008.00113.x. Addict Biol. 2008. PMID: 18482433 Free PMC article. Review.
-
Intrinsic effects of AM4113, a putative neutral CB1 receptor selective antagonist, on open-field behaviors in rats.Pharmacol Biochem Behav. 2008 Nov;91(1):84-90. doi: 10.1016/j.pbb.2008.06.014. Epub 2008 Jun 29. Pharmacol Biochem Behav. 2008. PMID: 18640150 Free PMC article.
-
Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol.Br J Pharmacol. 2009 Sep;158(1):183-94. doi: 10.1111/j.1476-5381.2009.00296.x. Epub 2009 Jul 7. Br J Pharmacol. 2009. PMID: 19594756 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
